June 16, 2024

Medical Trend

Medical News and Medical Resources

Analysis of the targets of new drugs on the global market in 2020

Analysis of the targets of new drugs on the global market in 2020


Analysis of the targets of new drugs on the global market in 2020.  In 2020, a total of 61 innovative drugs have been approved in the United States, the European Union and Japan, some of which have innovative biomolecular target mechanisms.

DrugAttributesTarget mechanismTarget classificationIndicationsApproval
Bempedoic acidSmall molecule inhibitorATP-citrate synthase (ACLY)EnzymeHypercholesterolemiaFDA,EMA
TazemetostatSmall molecule inhibitorHistone Lysine N-Methyltransferase EZH2 (EZH2)EnzymeEpithelioid sarcoma and follicular lymphomaFDA
LonafarnibSmall molecule inhibitorFarnesyltransferase (FPT)EnzymeHutchinson – Guildford Progeria Syndrome (HGPS) and Progeria-like LaminopathyFDA
CedazuridineSmall molecule inhibitorCytidine Dehydrogenase (CDA)EnzymeMyelodysplastic syndromeFDA
RemdesivirSmall molecule inhibitorSARS-CoV-2RNA-dependent RNA polymerase (RdRp)EnzymeCOVID-19FDA, EMA, PMDA
BulevirtidePeptidesSodium/bile acid transporter (SLC10A1)TransporterChronic hepatitis D virus infectionEMA
Ansuvimab ; atoltivimab , odesivimab , maftivimabMonoclonal antibodyEbola virus glycoprotein (EBOV GP)Viral glycoproteinEbola virus infectionFDA
Belantamab mafodotinAntibody Drugs (ADC)TNF receptor superfamily member 17 (TNFRSF17, BCMA)Tumor-associated antigenMultiple myelomaFDA,EMA
Sacituzumab  govitecanADCTumor-related calcium signal sensor 2 (TACSTD2, TROP2)Tumor-associated antigenTriple negative breast cancerFDA
LumasiransiRNAOxyacid oxidase 1 (HAO1)RNAType I hyperoxaluriaFDA,EMA
Borofalan(10B)10B-labeled BPA for Boron Neutron Capture Therapy (BNCT)Y+L amino acid transporter 1 (SLC7A7)TransporterHead and neck cancerPMDA
Ga 68 PSMA-11Imaging agentProstate specific antigen (KLK3)Tumor-associated antigenProstate cancer diagnosisFDA
Flortaucipir F 18Imaging agentMicrotubule-associated protein tau (MAPT)Structural skeletonAlzheimer’s disease (AD) diagnosisdrug
FDA (U.S. Food and Drug Administration), EMA (European Medicines Agency), PMDA (Japan Medicines and Medical Devices Agency)



Analysis of the targets of new drugs on the global market in 2020


Based on the analysis of literature, here are some of the important drugs and their targets.

Among the targets of the above-mentioned drugs, five (Bempedoic acid, Tazemetostat, Lonafarnib, Cedazuridine, Remdesivir) are enzymes that are inhibited by small molecule drugs, and four are human-derived proteins.

It is worth noting that the target protein of Remdesivir is SARS-CoV-2 RNA-dependent RNA polymerase, which is the first drug approved by the entire FDA to treat COVID-19.

Another viral target is the Ebola virus glycoprotein. For this protein, four innovative monoclonal antibodies (Ansuvimab, atoltivimab, odesivimab, maftivimab) have been approved, three of which are used as a combination therapy, and one can be a single agent.

In addition to small molecules and monoclonal antibodies, three other drug targets are based on therapeutic platforms. Two of them are antibody-drug conjugates (Belantamab mafodotin, Sacituzumab govitecan), which recognize the tumor-specific targets BCMA and TROP2, respectively, to selectively deliver cytotoxic components to tumor cells-the microtubule blocker monomethyl Austenite Bactericin F and topoisomerase I inhibitor SN-38.

The third drug lumasiran is the third approved small interfering RNA therapy, which treats rare disease type 1 hyperoxaluria by reducing the mRNA of oxyacid oxidase 1.

From the perspective of the therapeutic field, the above-mentioned seven innovative target mechanism drugs are used to treat rare diseases, including two family genetic diseases, two viral infections and three cancers.

In addition, there is a boron delivery agent (Borofalan) for tumor boron neutron capture therapy and two (Ga 68 PSMA-11, Flortaucipir F 18) for the diagnosis of prostate cancer and Alzheimer’s disease. The image agent is approved.




(source:internet, reference only)

Disclaimer of medicaltrend.org